Published in J Immunol on February 22, 2016
Dendritic cells and the control of immunity. Nature (1998) 56.54
Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol (2003) 15.65
BCL-2 family members and the mitochondria in apoptosis. Genes Dev (1999) 13.52
Graft-versus-host disease. Lancet (2009) 8.78
Communicable ulcerative colitis induced by T-bet deficiency in the innate immune system. Cell (2007) 8.42
T-bet regulates the terminal maturation and homeostasis of NK and Valpha14i NKT cells. Immunity (2004) 6.43
Prevention of graft versus host disease by inactivation of host antigen-presenting cells. Science (1999) 6.02
New IL-12-family members: IL-23 and IL-27, cytokines with divergent functions. Nat Rev Immunol (2005) 4.53
The transcription factor T-bet regulates mucosal T cell activation in experimental colitis and Crohn's disease. J Exp Med (2002) 4.47
The transcription factors T-bet and Eomes control key checkpoints of natural killer cell maturation. Immunity (2012) 4.32
Graft-versus-host disease. Nat Rev Immunol (2007) 4.26
Acute graft-versus-host disease does not require alloantigen expression on host epithelium. Nat Med (2002) 3.94
Advances in graft-versus-host disease biology and therapy. Nat Rev Immunol (2012) 3.50
CpG directly induces T-bet expression and inhibits IgG1 and IgE switching in B cells. Nat Immunol (2003) 3.41
Non-viral vectors for gene-based therapy. Nat Rev Genet (2014) 3.04
T-bet is essential for encephalitogenicity of both Th1 and Th17 cells. J Exp Med (2009) 2.96
T-bet regulates the fate of Th1 and Th17 lymphocytes in autoimmunity. J Immunol (2007) 2.86
TRAIL and apoptosis induction by TNF-family death receptors. Oncogene (2003) 2.75
Life and death by death receptors. FASEB J (2009) 2.39
T-bet is required for optimal production of IFN-gamma and antigen-specific T cell activation by dendritic cells. Proc Natl Acad Sci U S A (2003) 2.34
Donor APCs are required for maximal GVHD but not for GVL. Nat Med (2004) 2.18
Leukocyte migration and graft-versus-host disease. Blood (2005) 2.17
Natural killer (NK) cell-mediated cytotoxicity: differential use of TRAIL and Fas ligand by immature and mature primary human NK cells. J Exp Med (1998) 2.03
Preterminal host dendritic cells in irradiated mice prime CD8+ T cell-mediated acute graft-versus-host disease. J Clin Invest (2002) 1.98
Prevention of GVHD while sparing GVL effect by targeting Th1 and Th17 transcription factor T-bet and RORγt in mice. Blood (2011) 1.97
Host dendritic cells alone are sufficient to initiate acute graft-versus-host disease. J Immunol (2004) 1.91
T-bet deficiency reduces atherosclerosis and alters plaque antigen-specific immune responses. Proc Natl Acad Sci U S A (2005) 1.82
Pretransplant CSF-1 therapy expands recipient macrophages and ameliorates GVHD after allogeneic hematopoietic cell transplantation. J Exp Med (2011) 1.78
Induction of acute GVHD by sex-mismatched H-Y antigens in the absence of functional radiosensitive host hematopoietic-derived antigen-presenting cells. Blood (2011) 1.72
T-bet: a bridge between innate and adaptive immunity. Nat Rev Immunol (2013) 1.70
Acute rejection of murine bone marrow allografts by natural killer cells and T cells. Differences in kinetics and target antigens recognized. J Exp Med (1987) 1.56
IL-7 enhances peripheral T cell reconstitution after allogeneic hematopoietic stem cell transplantation. J Clin Invest (2003) 1.56
Transcription factor T-bet regulates inflammatory arthritis through its function in dendritic cells. J Clin Invest (2006) 1.49
Activation-induced death of mature T cells in the regulation of immune responses. Curr Opin Immunol (1995) 1.48
PKCtheta is required for alloreactivity and GVHD but not for immune responses toward leukemia and infection in mice. J Clin Invest (2009) 1.37
The role of antigen-presenting cells in triggering graft-versus-host disease and graft-versus-leukemia. Blood (2007) 1.37
Recipient nonhematopoietic antigen-presenting cells are sufficient to induce lethal acute graft-versus-host disease. Nat Med (2011) 1.34
The adjuvant activity of CpG DNA requires T-bet expression in dendritic cells. Proc Natl Acad Sci U S A (2005) 1.30
Effects of donor T-cell trafficking and priming site on graft-versus-host disease induction by naive and memory phenotype CD4 T cells. Blood (2008) 1.27
T-bet is essential for the progression of experimental autoimmune encephalomyelitis. Immunology (2006) 1.25
Beta2 integrins separate graft-versus-host disease and graft-versus-leukemia effects. Blood (2007) 1.23
Differential expression of inflammatory chemokines by Th1- and Th2-cell promoting dendritic cells: a role for different mature dendritic cell populations in attracting appropriate effector cells to peripheral sites of inflammation. Immunol Cell Biol (2005) 1.16
Host T cells resist graft-versus-host disease mediated by donor leukocyte infusions. J Immunol (2000) 1.11
Absence of Stat1 in donor CD4⁺ T cells promotes the expansion of Tregs and reduces graft-versus-host disease in mice. J Clin Invest (2011) 1.10
NK cell regulation of CD4 T cell-mediated graft-versus-host disease. J Immunol (2010) 1.10
NK cells regulating T cell responses: mechanisms and outcome. Trends Immunol (2015) 1.09
T-box transcription factor T-bet, a key player in a unique type of B-cell activation essential for effective viral clearance. Proc Natl Acad Sci U S A (2013) 1.08
Dendritic cells and regulation of graft-versus-host disease and graft-versus-leukemia activity. Blood (2012) 1.06
Pharmacologic inhibition of RORγt regulates Th17 signature gene expression and suppresses cutaneous inflammation in vivo. J Immunol (2014) 1.05
NK cells rapidly reject allogeneic bone marrow in the spleen through a perforin- and Ly49D-dependent, but NKG2D-independent mechanism. Am J Transplant (2007) 1.02
Contrasting alloreactive CD4+ and CD8+ T cells: there's more to it than MHC restriction. Am J Transplant (2003) 1.00
Adoptively transferred TRAIL+ T cells suppress GVHD and augment antitumor activity. J Clin Invest (2013) 0.96
Mechanisms underlying the induction of regulatory T cells and its relevance in the adaptive immune response in parasitic infections. Int J Biol Sci (2011) 0.95
Profound depletion of host conventional dendritic cells, plasmacytoid dendritic cells, and B cells does not prevent graft-versus-host disease induction. J Immunol (2012) 0.95
A small-molecule c-Rel inhibitor reduces alloactivation of T cells without compromising antitumor activity. Cancer Discov (2014) 0.93
The biology of graft-versus-host disease: experimental systems instructing clinical practice. Blood (2014) 0.90
c-Rel is an essential transcription factor for the development of acute graft-versus-host disease in mice. Eur J Immunol (2013) 0.87
Biology of graft-versus-host responses: recent insights. Biol Blood Marrow Transplant (2013) 0.86
Recipient NK cell inactivation and intestinal barrier loss are required for MHC-matched graft-versus-host disease. Sci Transl Med (2014) 0.85
Helper T-cell differentiation in graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Arch Immunol Ther Exp (Warsz) (2014) 0.83
TRAIL-transduced dendritic cells protect mice from acute graft-versus-host disease and leukemia relapse. J Immunol (2005) 0.83
T-bet is critical for the development of acute graft-versus-host disease through controlling T cell differentiation and function. J Immunol (2014) 0.82
The role of chemokines in mediating graft versus host disease: opportunities for novel therapeutics. Front Pharmacol (2012) 0.79
Reactivity of hybridomas derived from T cells activated in vivo during graft-versus-host disease. J Immunol (1994) 0.76